May 23, 2019

Rangaswamy Govindarajan, M.D., M.R.C.P.(U.K.)

Professor of Medicine
Division of Hematology/Oncology
Chief, Section of Hematology/Oncology, CAVHS
Quality Officer, Cancer Service Line
UAMS Winthrop P. Rockefeller Cancer Institute

Clinical Research Interest Statement

Dr. Govindarajan’s clinical interests are in the fields of gastrointestinal oncology and sarcoma. He treats patients with malignancy involving the entire GI tract, bone and soft tissue sarcomas. He is the principal investigator for Southwest Oncology Group (SWOG) studies and CTSU (Clinical Trials Services Unit). He also is a member of the gastrointestinal committee in SWOG. He is the section chief for Hematology and Oncology at Central Arkansas Veterans Healthcare System, where he also serves as the principal investigator for cooperative group trials.

Principal Investigator for Investigator-Initiated Studies

  1. Temazolamide in Renal Cell Carcinoma: Phase II Study. (Completed)
  2. Irinotecan and Thalidomide in Colorectal Carcinoma.(Completed)
  3. 5FU/Leucovorin/Irinotecan vs. 5FU/Leucovorin/Irinotecan/Thalidomide in metastatic colorectal carcinoma: A randomized phase II/III study conducted at multi-institutional level, to be initiated.
  4. Becvacizumab and erlotinib in the treatment of inoperable and metastatic hepatocellular carcinoma. Funded by Genentech, completed and published.
  5. Pilot Study: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth, stopped accrual.
  6. Phase II Study of low dose interleukin-2 (IL-2) and nivolumab for metastatic renal cell carcinoma

His current clinical research initiative on the role of re-exploration in incidental gall bladder cancer (IGBCA) is being worked through SWOG, and he serves as the principal investigator.

Principal Investigator for Cooperative Group Trials (UAMS)

  1. IRB# 203655 – S1320, “A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma.”
  2. IRB# 204351 – CTSU EAY131 Molecular Analysis for Therapy Choice (MATCH)
  3. IRB# 204603 – Alliance A091105 A Phase III, Double Blind, Randomized, Placebo Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
  4. IRB #66222 – CTSU E2805 ASSURE Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
  5. IRB #68239 – CTSU PACCT-1 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
  6. IRB #133529 – CTSU E1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
  7. IRB#132340- SWOG 0931, EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
  8. IRB #6809 – SWOG 0016 A Phase III Trial of CHOP vs CHOP Rituximab vs CHOP Iodine 131 Labeled Monoclonal Anti B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non Hodgkins Lymphomas
  9. IRB #26779 – SWOG E4697 A Randomized Placebo Controlled Phase III Trial of Yeast Derived CM CSF Versus Peptide Vaccination Versus GM CSF Plus Peptide Vaccination Versus Placebo in Patients with No Evidence of Disease after Complete Surgical Resection of Locally Advance and or Stage IV Melanoma
  10. IRB #28757 – SWOG CTSU E1697 Phase III Randomized Study of Four Weeks High Dose IFN a2b in Stage T2b No T3a bNo and T1 4 N1a 2a (microscopic) Melanoma
  11. IRB #29014 – SWOG 0221 Phase III Trial of Continuous Schedule AC G Vs Q 2 week Schedule AC Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Postoperative Adjuvant Therapy in Node Positive or High Risk Node Negative Breast Cancer

 

Principal Investigator for Trials at CAVHS

NCI Cooperative Group Open to Enrollment

EA6141 Melanoma

S1612 AML/MDS

S1616 Melanoma

EA5142 Lung

E4512 Lung

A151216 Lung

A081105 Lung

 

NCI Coop. Group Closed to Enrollment/Open to Continuing Review

E1208 HCC

E1609 Melanoma

E1305 H&N

E1A11 Mult. Myeloma

 

Cancer-Related Publications (Selected Publications Only)

  1. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, Tricot G. Preceding standard therapy is the likely cause of MDS after auto transplants for multiple myeloma.Br J Haematol. 1996 Nov; 95(2):349-53. PubMed PMID: 8904891.
  2. Munshi NC, Govindarajan R, Drake R, Ding LM, Iyer R, Saylors R, Kornbluth J, Marcus S, Chiang Y, Ennist D, Kwak L, Reynolds C, Tricot G, Barlogie B. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997 Feb 15; 89(4):1334-40. PubMed PMID: 9028956. Antiviral Res. 1997 Aug;35(3):177-85. PubMed PMID: 9298757.
  3. Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 2000 Aug 12; 356(9229):566-7. PubMed PMID: 10950238.
  4. Govindarajan R, Shah RV, Erkman LG, Hutchins LF. Racial differences in the outcome of patients with colorectal carcinoma. Cancer. 2003 Jan 15; 97(2):493-8. PubMed PMID: 12518374.
  5. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006 Oct 1; 24(28):e48. PubMed PMID: 17008686.
  6. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP.Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.J Clin Oncol. 2007 Apr 20; 25(12):1476-81. PubMed PMID: 17442990.
  7. Govindarajan R, Young JW, Harless CL, Hutchins LF. Barriers to clinical trials vary according to the type of trial and the institution.J Clin Oncol. 2007 Apr 20; 25(12):1633-4; author reply 1634. PubMed PMID: 17443010.
  8. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of Sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.Invest New Drugs. 2012 Aug; 30(4):1646-51. doi: 10.1007/s10637-011-9719-0. Epub 2011 Jul 12. PubMed PMID: 21748296; PubMed Central PMCID: PMC3490705.
  9. Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.Am J Clin Oncol. 2013 Jun; 36(3):254-7. doi: 10.1097/COC.0b013e318248d83f. PubMed PMID: 22643560.
  10. Kaur V, Mehta P, Johnsurd J, Govindarajan Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. Blood. 2014 Nov 27; 124 (23):3503-5. PMID 25431479.
  11. Rangaswamy Govindarajan, James Posey, Calvin Y. Chao, Ruixiao Lu, Trafina Jadhav, Ahmed Y. Javed, Awais Javed, Fade A. Mahmoud, Raymond U. Osarogiagbon and Upender Manne. A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer. BMC Cancer (2016) 16:368.
  12. Govindarajan R, Gujja S, Siegel ER, Batra A, Saeed A, Lai K, James JD, Fogel BJ, Williamson S. Programmed Cell Death-Logand1 (PD-L1) Expression in Anal Cancer. Am J Clin Oncol. 2018 Jul; 41(7):638-642. doi: 10.1097/COC.343. PMID: 27849650
  13. Incidence and Management of Olaratumab Infusion-Related Reactions. Brian A. Van Tine, M.D., Ph.D. Rangaswamy Govindarajan, MD Steven Attia, MD Neeta Somaiah, MD Scott S. Barker, MD Ashwin Shahir, MD Emily Barrett, BS Pablo Lee, MD Volker Wacheck, MD Samuel C. Ramage, MD William D. Tap, MD. Journal of Oncology Practice. (Accepted for Publication)

 

Dr. Govindarajan’s Collaborators

Stephen Williamson, M.D., Kansas University Medical Center, Kansas City, Kansas

Gurkamal Chatta, M.D., Roswell Park Cancer Institute, Buffalo, New York

SWOG GI Committee Office Bearers: (Drs. Milind Javle, El Khoueiry)

Brian Van Tine, M.D., Ph.D., Washington University, St. Louis, Missouri

Frank Simmen, Ph.D., UAMS

Dr. Govindarajan mentors residents and fellows on various clinical projects, some of which have resulted in national presentations, publications and awards.

You Might Not Know That

I enjoy biking, photography and travel. I gave up my ambition to obtain a pilot’s license (common sense prevailed!)